Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Other Accumulated Expenses (2021 - 2025)

Pliant Therapeutics (PLRX) has disclosed Other Accumulated Expenses for 5 consecutive years, with $4.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Accumulated Expenses fell 66.55% to $4.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.8 million, a 66.55% decrease, with the full-year FY2025 number at $4.8 million, down 66.55% from a year prior.
  • Other Accumulated Expenses was $4.8 million for Q4 2025 at Pliant Therapeutics, down from $7.8 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $23.0 million in Q3 2024 to a low of $4.8 million in Q4 2025.
  • A 5-year average of $13.4 million and a median of $14.0 million in 2023 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: skyrocketed 91.17% in 2022, then tumbled 66.55% in 2025.
  • Pliant Therapeutics' Other Accumulated Expenses stood at $5.9 million in 2021, then surged by 91.17% to $11.2 million in 2022, then grew by 11.04% to $12.5 million in 2023, then grew by 15.31% to $14.4 million in 2024, then crashed by 66.55% to $4.8 million in 2025.
  • Per Business Quant, the three most recent readings for PLRX's Other Accumulated Expenses are $4.8 million (Q4 2025), $7.8 million (Q3 2025), and $10.8 million (Q2 2025).